Calithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock
March 22 2017 - 07:00AM
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced the
pricing of its previously announced underwritten public offering of
6,830,000 shares of its common stock at a price to the public of
$10.25 per share. Gross proceeds to Calithera from the
offering are expected to be approximately $70.0 million, before
deducting underwriting discounts and commissions and estimated
offering expenses. All of the shares of common stock are
being offered by Calithera. In addition, Calithera has granted the
underwriters a 30-day option to purchase up to 1,024,500 of
additional shares of common stock at the public offering
price. The offering is expected to close on March 27, 2017,
subject to customary closing conditions.
Leerink Partners is acting as sole book-running
manager for the offering. Wells Fargo Securities is acting as a
lead manager and JMP Securities is acting as a co-manager for the
offering.
A shelf registration statement relating to the
offered shares of common stock was filed with the Securities and
Exchange Commission (SEC), and was declared effective on November
24, 2015. A preliminary prospectus supplement and
accompanying prospectus relating to the offering have been filed
with the SEC and are available on the SEC’s website, located at
www.sec.gov. Copies of the final prospectus supplement and
accompanying prospectus related to the offering may be obtained,
when available, from Leerink Partners LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA,
02110, by email at syndicate@leerink.com, or by telephone at (800)
808-7525, ext. 6132.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer. Calithera is
headquartered in South San Francisco, California.
Investor Relations Contact:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2023 to Mar 2024